This scenario has therefore prompted the search of molecular agents targeting the Eph-ephrin system with a two-fold aim: (i) confirming the relevance of clinical data reported in the literature; and (ii) designing an efficient strategy based on biologics and small molecules to interact with targets of this elusive system in cancer therapy. Here, EPHA1 is linked to cancer.